1-(difluoromethyl)-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole → 1-(6-(1,4-Diazepan-1-yl)pyridin-2-yl)-6-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridine

HRID 57879

Reaktionsgleichung

Reaktionsgleichung von HRID 57879
Cl[C:2]1[N:7]=[CH:6][C:5]2[CH:8]=[N:9][N:10]([C:11]3[N:16]=[C:15]([N:17]4[CH2:23][CH2:22][CH2:21][N:20](C(OC(C)(C)C)=O)[CH2:19][CH2:18]4)[CH:14]=[CH:13][CH:12]=3)[C:4]=2[CH:3]=1.[F:31][CH:32]([F:47])[N:33]1[CH:37]=[C:36](B2OC(C)(C)C(C)(C)O2)[CH:35]=[N:34]1>>[N:17]1([C:15]2[N:16]=[C:11]([N:10]3[C:4]4[CH:3]=[C:2]([C:36]5[CH:35]=[N:34][N:33]([CH:32]([F:31])[F:47])[CH:37]=5)[N:7]=[CH:6][C:5]=4[CH:8]=[N:9]3)[CH:12]=[CH:13][CH:14]=2)[CH2:23][CH2:22][CH2:21][NH:20][CH2:19][CH2:18]1

Komponenten

3

Versuchsvorschrift

Following the procedures as described in Example 45 and starting with tert-butyl 4-(6-(6-chloro-1H-pyrazolo[4,3-c]pyridin-1-yl)pyridin-2-yl)-1,4-diazepane-1-carboxylate and 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, 173 was obtained as a white solid (80 mg, 35%) over three steps. 1H-NMR (500 MHz, CD3OD) δ (ppm) 9.06 (s, 1H), 8.73 (s, 1H), 8.50 (s, 1H), 8.34 (s, 1H), 8.15 (s, 1H), 7.50-7.67 (m, 2H), 7.23 (d, J=7.5 Hz, 1H), 6.58 (d, J=8.0 Hz, 1H), 3.87-3.90 (m, 4H), 3.13-3.15 (m, 2H), 2.91-2.94 (m, 2H), 2.03-2.08 (m, 2H); MS (ESI) m/z: 411 [M+H]+.

Quellen und Nachweise

ORD-Eintrag
ord-a3f73193c3574d4899db0c9ae52928ae
Quelldatensatz
uspto-grants-2016_09
Patentnummer
US09434725B2

Verknüpfte Notizen

Wird geladen…